Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.
2.
3.

Application of immunohistochemistry to the diagnosis of malignant mesothelioma.

Marchevsky AM.

Arch Pathol Lab Med. 2008 Mar;132(3):397-401. doi: 10.1043/1543-2165(2008)132[397:AOITTD]2.0.CO;2. Review.

PMID:
18318582
4.
5.

The immunohistochemical diagnosis of epithelial mesothelioma.

Ordóñez NG.

Hum Pathol. 1999 Mar;30(3):313-23. Review.

PMID:
10088551
7.
8.

In search of a positive immunohistochemical marker for mesothelioma: an update.

Ordóñez NG.

Adv Anat Pathol. 1998 Jan;5(1):53-60. Review. No abstract available.

PMID:
9868512
9.

[New diagnostic markers for malignant pleural mesothelioma].

Grigoriu BD, Grégoire M, Chahine B, Scherpereel A.

Bull Cancer. 2008 Feb;95(2):177-84. doi: 10.1684/bdc.2008.0576. Review. French.

PMID:
18304902
10.

Serum and pleural fluid biomarkers for mesothelioma.

Creaney J, Robinson BW.

Curr Opin Pulm Med. 2009 Jul;15(4):366-70. doi: 10.1097/MCP.0b013e32832b98eb. Review.

PMID:
19417672
11.

Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis.

Chekol SS, Sun CC.

Arch Pathol Lab Med. 2012 Jan;136(1):113-7. doi: 10.5858/arpa.2010-0550-RS. Review.

PMID:
22208496
12.

Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.

Ordóñez NG.

Hum Pathol. 2013 Jan;44(1):1-19. doi: 10.1016/j.humpath.2012.05.014. Epub 2012 Sep 7. Review.

PMID:
22963903
13.

Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.

Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, Churg A, Dacic S, Fraire A, Galateau-Salle F, Gibbs A, Gown A, Hammar S, Litzky L, Marchevsky AM, Nicholson AG, Roggli V, Travis WD, Wick M; International Mesothelioma Interest Group.

Arch Pathol Lab Med. 2013 May;137(5):647-67. doi: 10.5858/arpa.2012-0214-OA. Epub 2012 Aug 28.

PMID:
22929121
14.

Epithelioid lesions of the serosa.

Anttila S.

Arch Pathol Lab Med. 2012 Mar;136(3):241-52. doi: 10.5858/arpa.2010-0216-RA. Review.

PMID:
22372900
15.

Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features.

Taşkın S, Gümüş Y, Kiremitçi S, Kahraman K, Sertçelik A, Ortaç F.

Int J Clin Exp Pathol. 2012;5(5):472-8. Epub 2012 May 23. Review.

16.

The established and future biomarkers of malignant pleural mesothelioma.

Panou V, Vyberg M, Weinreich UM, Meristoudis C, Falkmer UG, Røe OD.

Cancer Treat Rev. 2015 Jun;41(6):486-95. doi: 10.1016/j.ctrv.2015.05.001. Epub 2015 May 8. Review.

PMID:
25979846
17.

Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.

Betta PG, Magnani C, Bensi T, Trincheri NF, Orecchia S.

Arch Pathol Lab Med. 2012 Mar;136(3):253-61. doi: 10.5858/arpa.2010-0604-RA. Review.

PMID:
22372901
18.

Mesothelin: a new target for immunotherapy.

Hassan R, Bera T, Pastan I.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42. Review.

19.

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.

Pantazopoulos I, Boura P, Xanthos T, Syrigos K.

Eur Respir J. 2013 Mar;41(3):706-15. doi: 10.1183/09031936.00226111. Epub 2012 Jul 26. Review.

20.

Malignant Mesothelioma Diagnosis.

Arif Q, Husain AN.

Arch Pathol Lab Med. 2015 Aug;139(8):978-80. doi: 10.5858/arpa.2013-0381-RA. Review.

PMID:
26230591
Items per page

Supplemental Content

Write to the Help Desk